Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Schwarzer

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Cancer Research and Clinical Oncology|August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world studySong-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Journal of Cancer Research and Clinical Oncology|May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myelomaWolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology|June 20, 2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myelomaWolfram Pönisch, Bruno Holzvogt, Madlen Plötze, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Cancer Research and Clinical Oncology|August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world studySong-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Journal of Cancer Research and Clinical Oncology|May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myelomaWolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology|June 20, 2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myelomaWolfram Pönisch, Bruno Holzvogt, Madlen Plötze, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 4